. 2019 Nov;19(1).
doi: 10.1007/s10689-019-00153-5.

Radiotherapy-induced malignancies in breast cancer patients with TP53 pathogenic germline variants (Li-Fraumeni syndrome)

Vanessa Petry 1 Renata Colombo Bonadio 2 Allyne Queiroz Carneiro Cagnacci 2 Luiz Antonio Leite Senna 2 Roberta do Nascimento Galvão Campos 2 Guilherme Cutait Cotti 2 Paulo M Hoff 2 Maria Candida Barisson Villares Fragoso 2 Maria Del Pilar Estevez-Diz 2 
  • PMID: 31748977
  •     35 References
  •     2 citations


The risk of radiotherapy-induced malignancies (RIMs) is a concern when treating Li-Fraumeni syndrome (LFS) or Li-Fraumeni Like (LFL) patients. However, the type of TP53 pathogenic germline variant may possibly influence this risk. TP53 p.R337H mutation is particularly prevalent in Brazil. We aimed to evaluate the outcomes of patients with pathogenic TP53 variants treated for localized breast cancer in a Brazilian cohort. We evaluated retrospectively a cohort of patients with germline TP53 pathogenic variants treated for localized breast cancer between December 1999 and October 2017. All patients were followed by the Hereditary Cancer Group of an academic cancer center. Our primary objective was to evaluate the occurrence of RIMs after adjuvant radiotherapy. Sixteen patients were evaluated; 10 (62.5%) had a germline TP53 p.R337H pathogenic variant. Median age was 39.8 years. Thirteen patients had invasive ductal carcinoma: 8 (61.5%) were hormone receptor-positive; 6 (46.1%), human epithelial growth factor receptor 2 (HER2)-amplified. Three patients had ductal carcinoma in situ. Most patients (N = 12/16, 75%) received adjuvant radiotherapy. After a median follow-up of 52.5 months, 2 patients (2/12, 16.6%) had RIMs. One had a fibrosarcoma and the other, a low-grade leiomyosarcoma. In the group treated with radiotherapy, one distant recurrence was diagnosed (1/12), and no loco-regional recurrence occurred. Among 4 patients who did not receive radiotherapy, 2 presented with loco-regional recurrence. In this cohort of patients with LFS enriched in TP53 p.R337H pathogenic variant, the incidence of RIMs after treatment of localized breast cancer was lower than previous literature. Nevertheless, rates of RIMs were still alarming. Early molecular diagnosis and careful evaluation of treatment risks and benefits are essential for these patients.

Keywords: Breast cancer; Li–Fraumeni; Radiotherapy; Radiotherapy-induced malignancies; TP53.

Radiation dose, chemotherapy, hormonal treatment and risk of second cancer after breast cancer treatment.
C Rubino, F de Vathaire, +2 authors, M G Lê.
Br J Cancer, 2003 Aug 28; 89(5). PMID: 12942115    Free PMC article.
Breast cancer in young women: poor survival despite intensive treatment.
Hanna Fredholm, Sonja Eaker, +3 authors, Henrik Lindman.
PLoS One, 2009 Nov 13; 4(11). PMID: 19907646    Free PMC article.
Highly Cited.
Germline mutations in the TP53 gene.
R A Eeles.
Cancer Surv, 1995 Jan 01; 25. PMID: 8718514
Chest wall sarcoma: 18F-FDG PET/CT in a patient with Li-Fraumeni syndrome.
Tyson Chadaz, Susan K Hobbs, Hongju Son.
Clin Nucl Med, 2013 Oct 11; 38(10). PMID: 24107814
Li-fraumeni syndrome.
David Malkin.
Genes Cancer, 2011 Jul 23; 2(4). PMID: 21779515    Free PMC article.
Highly Cited.
[Radiation-induced intracranial osteosarcoma after radiation for acute lymphocytic leukemia associated with Li-Fraumeni syndrome].
Junichi Yoshimura, Manabu Natsumeda, +5 authors, Yukihiko Fujii.
No Shinkei Geka, 2013 Jun 05; 41(6). PMID: 23732761
Heterogeneity of Li-Fraumeni syndrome links to unequal gain-of-function effects of p53 mutations.
Jie Xu, Jin Qian, +4 authors, Jing-Yuan Fang.
Sci Rep, 2014 Feb 28; 4. PMID: 24573247    Free PMC article.
Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype.
Magali Olivier, David E Goldgar, +4 authors, Rosalind A Eeles.
Cancer Res, 2003 Oct 30; 63(20). PMID: 14583457
Highly Cited.
Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.
Sue Richards, Nazneen Aziz, +10 authors, ACMG Laboratory Quality Assurance Committee.
Genet Med, 2015 Mar 06; 17(5). PMID: 25741868    Free PMC article.
Highly Cited.
TP53 germline mutation may affect response to anticancer treatments: analysis of an intensively treated Li-Fraumeni family.
Sonja Kappel, Elisabeth Janschek, +4 authors, Daniela Kandioler.
Breast Cancer Res Treat, 2015 May 20; 151(3). PMID: 25981898
Radiation-associated Angiosarcoma Mimicking Fallopian Tube High-grade Serous Carcinoma in a Woman With De Novo Li-Fraumeni Syndrome.
Sarah M Crafton, Leigha Senter-Jamieson, +2 authors, Adrian A Suarez.
Int J Gynecol Pathol, 2018 Apr 06; 38(3). PMID: 29620582
Two metachronous tumors in the radiotherapy fields of a patient with Li-Fraumeni syndrome.
J M Limacher, T Frebourg, S Natarajan-Ame, J P Bergerat.
Int J Cancer, 2001 Jul 28; 96(4). PMID: 11474498
Angiosarcoma in previously irradiated breast in patient with Li-Fraumeni syndrome. A case report.
Oséias Vargas Barbosa, André Borba Reiriz, +2 authors, Luiza Rossi.
Sao Paulo Med J, 2014 Oct 02; 133(2). PMID: 25271877
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.
Joseph A Sparano, Robert J Gray, +27 authors, George W Sledge.
N Engl J Med, 2019 Jun 04; 380(25). PMID: 31157962    Free PMC article.
Highly Cited.
VarSome: the human genomic variant search engine.
Christos Kopanos, Vasilis Tsiolkas, +4 authors, Andreas Massouras.
Bioinformatics, 2018 Oct 31; 35(11). PMID: 30376034    Free PMC article.
Highly Cited.
Radio-induced malignancies after breast cancer postoperative radiotherapy in patients with Li-Fraumeni syndrome.
Steve Heymann, Suzette Delaloge, +7 authors, Céline Bourgier.
Radiat Oncol, 2010 Nov 10; 5. PMID: 21059199    Free PMC article.
Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms.
D Malkin, F P Li, +7 authors, M A Tainsky.
Science, 1990 Dec 10; 250(4985). PMID: 1978757
Highly Cited.
Clinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer.
Terri P McVeigh, Michael J Kerin.
Breast Cancer (Dove Med Press), 2017 Jun 16; 9. PMID: 28615971    Free PMC article.
Chest wall leiomyosarcoma after breast-conservative therapy for early-stage breast cancer in a young woman with Li-Fraumeni syndrome.
Eve Henry, Victor Villalobos, +6 authors, Melinda L Telli.
J Natl Compr Canc Netw, 2012 Aug 11; 10(8). PMID: 22878818
Rapid development of post-radiotherapy sarcoma and breast cancer in a patient with a novel germline 'de-novo' TP53 mutation.
A Salmon, D Amikam, +5 authors, T Peretz.
Clin Oncol (R Coll Radiol), 2007 Jun 19; 19(7). PMID: 17572079
Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families.
J M Birch, A L Hartley, +7 authors, D Crowther.
Cancer Res, 1994 Mar 01; 54(5). PMID: 8118819
Highly Cited.
A cancer family syndrome in twenty-four kindreds.
F P Li, J F Fraumeni, +4 authors, R W Miller.
Cancer Res, 1988 Sep 15; 48(18). PMID: 3409256
Highly Cited.
Are there low-penetrance TP53 Alleles? evidence from childhood adrenocortical tumors.
J M Varley, G McGown, +7 authors, J M Birch.
Am J Hum Genet, 1999 Sep 16; 65(4). PMID: 10486318    Free PMC article.
Contribution of genotoxic anticancer treatments to the development of multiple primary tumours in the context of germline TP53 mutations.
Edwige Kasper, Emilie Angot, +9 authors, Gaëlle Bougeard.
Eur J Cancer, 2018 Aug 04; 101. PMID: 30072235
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.
Hongchao Pan, Richard Gray, +9 authors, EBCTCG.
N Engl J Med, 2017 Nov 09; 377(19). PMID: 29117498    Free PMC article.
Highly Cited.
The Inherited p53 Mutation in the Brazilian Population.
Maria Isabel Achatz, Gerard P Zambetti.
Cold Spring Harb Perspect Med, 2016 Sep 25; 6(12). PMID: 27663983    Free PMC article.
Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations.
Kelly D Gonzalez, Katie A Noltner, +8 authors, Jeffrey N Weitzel.
J Clin Oncol, 2009 Feb 11; 27(8). PMID: 19204208
Highly Cited.
Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers.
Gaëlle Bougeard, Mariette Renaux-Petel, +15 authors, Thierry Frebourg.
J Clin Oncol, 2015 May 28; 33(21). PMID: 26014290
Highly Cited.
Clinical implications of germline mutations in breast cancer: TP53.
Katherine Schon, Marc Tischkowitz.
Breast Cancer Res Treat, 2017 Oct 19; 167(2). PMID: 29039119    Free PMC article.
Radiation-induced angiosarcoma of the breast in a Li-Fraumeni patient.
Alejandra García Novoa, Benigno Acea Nebril, +2 authors, Silvia Antolín Novoa.
Cir Esp, 2018 Jul 14; 97(2). PMID: 30001797
Breast cancer in patients with Li-Fraumeni syndrome - a case-series study and review of literature.
Amara G Nandikolla, Sangeetha Venugopal, Jesus Anampa.
Breast Cancer (Dove Med Press), 2017 Mar 31; 9. PMID: 28356770    Free PMC article.
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update.
Ian Krop, Nofisat Ismaila, +10 authors, Vered Stearns.
J Clin Oncol, 2017 Jul 12; 35(24). PMID: 28692382    Free PMC article.
Highly Cited.
Pathologic complete response and overall survival in breast cancer subtypes in stage III inflammatory breast cancer.
Dominique J P van Uden, Marissa C van Maaren, +5 authors, Johannes H W de Wilt.
Breast Cancer Res Treat, 2019 Apr 12; 176(1). PMID: 30972613    Free PMC article.
Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome?
F P Li, J F Fraumeni.
Ann Intern Med, 1969 Oct 01; 71(4). PMID: 5360287
Highly Cited.
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.
Patricia Cortazar, Lijun Zhang, +34 authors, Gunter von Minckwitz.
Lancet, 2014 Feb 18; 384(9938). PMID: 24529560
Highly Cited. Review.
Is CHEK2 a moderate-risk breast cancer gene or the younger sister of Li-Fraumeni?
Dilanka L De Silva, Ingrid Winship.
BMJ Case Rep, 2020 Sep 10; 13(9). PMID: 32900738    Free PMC article.
Identification of the potential roles of ring finger protein 8 in TP53-mutant breast cancer.
Feng Zhao, Peibin Wang, +6 authors, Chaoqian Liu.
Oncol Lett, 2020 Dec 03; 21(1). PMID: 33262834    Free PMC article.